NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
1. Financial Statement Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and the rules of the Securities and Exchange Commission (the "SEC"). Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to those rules and regulations. The December 31, 2015 condensed consolidated balance sheet was derived from audited financial statements. The financial statements include adjustments consisting of normal recurring items, which, in the opinion of management, are necessary for a fair presentation of the financial position of On Assignment, Inc. and its subsidiaries (the "Company") and its results of operations for the interim dates and periods set forth herein. The results for any of the interim periods are not necessarily indicative of the results to be expected for the full year or any other period. This Quarterly Report on Form 10-Q should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended
December 31, 2015
("
2015
10-K").
2. Accounting Standards Update
In April 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update ("ASU") No. 2015-05,
Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40)
. ASU No. 2015-05 provides guidance to customers about whether a cloud computing arrangement includes a software license. If a cloud computing arrangement includes a software license, then the customer should account for the software license element of the arrangement consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. It is effective for annual periods (including interim periods) beginning after December 15, 2015, and early adoption is permitted. The Company prospectively adopted ASU 2015-05 as of January 1, 2016, with no impact to its consolidated financial statements.
In February 2016, the FASB issued ASU No. 2016-02,
Leases (Topic 842)
, which is intended to improve financial reporting about leasing transactions. This standard requires a lessee to record on the balance sheet the assets and liabilities for the rights and obligations created by lease terms of more than 12 months. It is effective for annual periods (including interim periods) beginning after December 15, 2018, and early adoption is permitted. The Company is currently evaluating the impact the provisions of ASU 2016-02 will have on its consolidated financial statements.
In March 2016, the FASB issued ASU No. 2016-09,
Compensation - Stock Compensation (Topic 718)
, which is intended to simplify the accounting for the taxes related to stock-based compensation, including adjustments to how excess tax benefits and a company's payments for tax withholdings should be classified. It is effective for annual periods (including interim periods) beginning after December 15, 2016, and early adoption is permitted. The Company is currently evaluating the impact the provisions of ASU 2016-09 will have on its consolidated financial statements.
In May 2014, the FASB issued ASU No. 2014-09,
Revenue from Contracts with Customers (Topic 606)
, which outlines a comprehensive new revenue recognition model designed to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In March 2016, the FASB issued ASU No. 2016-08,
Revenue from Contracts with Customers (Topic 606)
-
Principal versus Agent Considerations (Reporting Revenue Gross versus Net)
,
which further clarifies the implementation guidance on principal versus agent considerations contained in ASU 2014-09. In April 2016, the FASB issued ASU No. 2016-10,
Revenue from Contracts with Customers (Topic 606)
-
Identifying Performance Obligations and Licensing
, which further clarifies the implementation guidance relating to identifying performance obligations and the licensing implementation guidance. These standards, pursuant to ASU No. 2015-14,
Revenue from Contracts with Customers
-
Deferral of the Effective Date (Topic 606)
issued by the FASB in August 2015, will be effective for annual periods (including interim periods) beginning after December 15, 2017. The Company is currently evaluating the impact these provisions will have on its consolidated financial statements.
3. Acquisitions
On
June 5, 2015
, the Company acquired all of the outstanding shares of the holding company for
Creative Circle, LLC
("Creative Circle"). Creative Circle, which
is headquartered in Los Angeles, California
,
was purchased to expand the Company’s technical and creative staffing services
. The purchase price consisted of
$540.0 million
cash,
$30.2 million
of common stock (
794,700
shares of the Company’s common stock), and estimated future contingent consideration which was valued at
$13.8 million
. Goodwill related to this acquisition totaled
$358.0 million
, and is deductible for income tax purposes. Acquisition expenses of approximately
$5.7 million
were expensed in 2015 and are included in selling, general and administrative expenses ("SG&A"). The results of operations for the acquisition have been combined with those of the Company from the acquisition date.
On
April 14, 2015
, the Company acquired all of the outstanding shares of
LabResource B.V.
("LabResource")
headquartered in Amsterdam, Netherlands
for
$12.7 million
. LabResource was purchased to
expand the Company's life sciences staffing business in Europe
. Goodwill associated with this acquisition is not deductible for tax purposes. Acquisition expenses of approximately
$0.4 million
were expensed in 2015 and are included in SG&A. The results of operations for this acquisition have been combined with those of the Company from the acquisition date.
Assets and liabilities of the acquired companies were recorded at their estimated fair values at the dates of acquisition. The excess purchase price over the fair value of net tangible assets and identifiable intangible assets acquired has been allocated to goodwill. The fair value assigned to identifiable intangible assets was determined primarily by using a discounted cash flow method. The Company's allocation of the purchase price of Creative Circle and LabResource has been finalized and the
following table summarizes the allocations (in thousands):
|
|
|
|
|
|
|
|
|
|
Creative Circle
|
|
LabResource
|
Cash
|
$
|
4,840
|
|
|
$
|
187
|
|
Accounts receivable
|
34,386
|
|
|
1,643
|
|
Prepaid expenses and other current assets
|
4,462
|
|
|
—
|
|
Property and equipment
|
5,077
|
|
|
12
|
|
Goodwill
|
358,029
|
|
|
6,449
|
|
Identifiable intangible assets
|
194,500
|
|
|
7,528
|
|
Other
|
651
|
|
|
—
|
|
Total assets acquired
|
$
|
601,945
|
|
|
$
|
15,819
|
|
|
|
|
|
Current liabilities
|
$
|
12,254
|
|
|
$
|
1,482
|
|
Other
|
—
|
|
|
1,882
|
|
Total liabilities assumed
|
12,254
|
|
|
3,364
|
|
Total purchase price
(1) (2)
|
$
|
589,691
|
|
|
$
|
12,455
|
|
|
|
(1)
|
Excluding cash acquired and a $0.9 million adjustment for net working capital in excess of the targeted amount (thereby increasing the actual purchase price paid), the purchase price for Creative Circle was $584.0 million as described in the discussion above.
|
|
|
(2)
|
Excluding cash acquired and a $0.4 million adjustment for net working capital that was less than the targeted amount (thereby reducing the actual purchase price paid), the purchase price for LabResource was $12.7 million as described in the discussion above.
|
The following table summarizes (in thousands) the allocation of the purchase price among the identifiable intangible assets for the acquisitions:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Identifiable Intangible Asset Value
|
|
Useful life
|
|
Creative Circle
|
|
LabResource
|
Contractor relationships
|
2 - 4 years
|
|
$
|
29,500
|
|
|
$
|
947
|
|
Customer relationships
|
2 - 10 years
|
|
90,700
|
|
|
5,421
|
|
Non-compete agreements
|
2 - 6 years
|
|
7,300
|
|
|
20
|
|
Favorable contracts
|
5 years
|
|
900
|
|
|
—
|
|
Trademarks
|
indefinite
|
|
66,100
|
|
|
1,140
|
|
Total identifiable intangible assets acquired
|
|
$
|
194,500
|
|
|
$
|
7,528
|
|
The summary below (in thousands, except for per share data) presents pro forma unaudited consolidated results of operations for the three months ended March 31, 2015 as if the acquisitions of Creative Circle and LabResource occurred on January 1, 2014. The pro forma financial information gives effect to certain adjustments, including amortization of intangible assets, interest expense on acquisition-related debt, provision for income taxes, and increased number of common shares as a result of the acquisitions. Acquisition-related costs are assumed to have occurred at the beginning of the year prior to acquisition. The pro forma financial information is not necessarily indicative of the operating results that would have occurred if the acquisitions had been consummated as of the date indicated, nor are they necessarily indicative of future operating results.
|
|
|
|
|
Revenues
|
$
|
494,708
|
|
Income from continuing operations
|
$
|
13,955
|
|
Net income
|
$
|
40,067
|
|
|
|
Basic earnings per share:
|
|
Income from continuing operations
|
$
|
0.27
|
|
Net income
|
$
|
0.77
|
|
|
|
Diluted earnings per share:
|
|
Income from continuing operations
|
$
|
0.26
|
|
Net income
|
$
|
0.76
|
|
|
|
Number of shares and share equivalents used to calculate earnings per share:
|
|
Basic
|
52,314
|
|
Diluted
|
53,046
|
|
4. Discontinued Operations
On February 1, 2015, the Company completed the sale of its Physician Segment for
$123.0 million
including
$6.0 million
that was held in escrow and was released in March 2016. The gain on the sale was
$25.7 million
(net of income taxes of
$14.4 million
). The operating results of this segment are presented as discontinued operations in the condensed consolidated statements of operations and comprehensive income for all periods presented.
Cash flows from discontinued operations are included in the condensed consolidated statements of cash flows for the
three months ended March 31, 2016
and
2015
. The cash flows that are attributable to the Physician Segment are as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
March 31,
|
|
2016
|
|
2015
|
Net cash provided by (used in) operating activities
|
$
|
53
|
|
|
$
|
(1,778
|
)
|
|
|
|
|
Net cash provided by investing activities:
|
|
|
|
Cash received from sale of discontinued operations, net
|
$
|
6,000
|
|
|
$
|
114,884
|
|
Other
|
—
|
|
|
(14
|
)
|
Total cash provided by investing activities
|
$
|
6,000
|
|
|
$
|
114,870
|
|
The following is a summary of the operating results of all of the Company's discontinued operations (in thousands):
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
March 31,
|
|
2016
|
|
2015
|
Revenues
|
$
|
—
|
|
|
$
|
12,068
|
|
Costs of services
|
—
|
|
|
8,653
|
|
Gross profit
|
—
|
|
|
3,415
|
|
Selling, general and administrative expenses
|
(85
|
)
|
|
2,641
|
|
Amortization of intangible assets
|
—
|
|
|
155
|
|
Income before income taxes
|
85
|
|
|
619
|
|
Provision for income taxes
|
32
|
|
|
210
|
|
Income from discontinued operations, net of income taxes
|
$
|
53
|
|
|
$
|
409
|
|
5. Goodwill and Identifiable Intangible Assets
The changes in the carrying amount of goodwill for the year ended
December 31, 2015
and the
three months ended
March 31, 2016
are as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Apex Segment
|
|
Oxford Segment
|
|
Total
|
Balance as of December 31, 2014
|
$
|
287,951
|
|
|
$
|
224,109
|
|
|
$
|
512,060
|
|
Creative Circle Acquisition
|
358,029
|
|
|
—
|
|
|
358,029
|
|
LabResource Acquisition
|
—
|
|
|
6,449
|
|
|
6,449
|
|
Translation adjustment
|
(1,363
|
)
|
|
(269
|
)
|
|
(1,632
|
)
|
Balance as of December 31, 2015
|
644,617
|
|
|
230,289
|
|
|
874,906
|
|
Translation adjustment
|
355
|
|
|
396
|
|
|
751
|
|
Balance as of March 31, 2016
|
$
|
644,972
|
|
|
$
|
230,685
|
|
|
$
|
875,657
|
|
Acquired intangible assets consisted of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of March 31, 2016
|
|
As of December 31, 2015
|
|
Estimated Useful Life
|
|
Gross Carrying Amount
|
|
Accumulated Amortization
|
|
Net Carrying Amount
|
|
Gross Carrying Amount
|
|
Accumulated Amortization
|
|
Net Carrying Amount
|
Subject to amortization:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Customer relationships
|
2 - 10 years
|
|
$
|
196,780
|
|
|
$
|
80,781
|
|
|
$
|
115,999
|
|
|
$
|
196,472
|
|
|
$
|
74,640
|
|
|
$
|
121,832
|
|
Contractor relationships
|
2 - 5 years
|
|
69,813
|
|
|
42,991
|
|
|
26,822
|
|
|
69,764
|
|
|
40,124
|
|
|
29,640
|
|
Non-compete agreements
|
2 - 7 years
|
|
10,889
|
|
|
3,626
|
|
|
7,263
|
|
|
10,874
|
|
|
3,163
|
|
|
7,711
|
|
In-use software
|
6 years
|
|
18,900
|
|
|
7,304
|
|
|
11,596
|
|
|
18,900
|
|
|
6,516
|
|
|
12,384
|
|
Favorable contracts
|
5 years
|
|
900
|
|
|
242
|
|
|
658
|
|
|
900
|
|
|
172
|
|
|
728
|
|
|
|
|
297,282
|
|
|
134,944
|
|
|
162,338
|
|
|
296,910
|
|
|
124,615
|
|
|
172,295
|
|
Not subject to amortization:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Trademarks
|
|
|
245,761
|
|
|
—
|
|
|
245,761
|
|
|
245,630
|
|
|
—
|
|
|
245,630
|
|
Total
|
|
|
$
|
543,043
|
|
|
$
|
134,944
|
|
|
$
|
408,099
|
|
|
$
|
542,540
|
|
|
$
|
124,615
|
|
|
$
|
417,925
|
|
Amortization expense for intangible assets with finite lives was
$10.1 million
and
$4.9 million
for the
three months ended March 31, 2016
and
2015
, respectively. Estimated amortization expense for the remainder of this year, each of the next four years, and thereafter is as follows (in thousands):
|
|
|
|
|
2016
|
$
|
29,515
|
|
2017
|
33,054
|
|
2018
|
28,928
|
|
2019
|
22,016
|
|
2020
|
14,515
|
|
Thereafter
|
34,310
|
|
|
$
|
162,338
|
|
Goodwill and other intangible assets having an indefinite useful life are not amortized for financial statement purposes. These assets are reviewed for impairment on an annual basis as of October 31 and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. There w
ere
no
triggerin
g events that required an interim impairment analysis during the current period.
6. Long-Term Debt
Long-term debt consisted of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
March 31,
2016
|
|
December 31,
2015
|
$150 million revolving credit facility, due June 2020
|
$
|
34,000
|
|
|
$
|
50,000
|
|
$825 million Term B loan facility, due June 2022
|
707,000
|
|
|
724,000
|
|
|
741,000
|
|
|
774,000
|
|
Unamortized deferred loan costs
|
(17,781
|
)
|
|
(18,492
|
)
|
|
$
|
723,219
|
|
|
$
|
755,508
|
|
On June 5, 2015, the Company entered into a new
$975.0 million
credit facility. The funds were used to repay the old credit facility and to fund the cash portion of the purchase of Creative Circle (see "Note
3. Acquisitions
"). The new facility consists of (i) an
$825.0 million
seven-year term B loan facility and (ii) a
$150.0 million
five-year revolving loan facility. Under terms of the new facility, the Company has the ability to increase the principal amount of the loan facilities.
Borrowings under the term B loan bear interest at LIBOR (floor of 75 basis points), plus
3.0 percent
and borrowings under the revolving credit facility bear interest at LIBOR (or the bank’s base rate) plus
0.75
to
2.5 percent
depending on leverage levels. A commitment fee of
0.25
to
0.40 percent
is payable on the undrawn portion of the revolving credit facility. At
March 31, 2016
, the weighted average interest rate was
3.7 percent
.
Under terms of the credit facility, the Company was required to make minimum quarterly payments of
$2.1 million
. Through
March 31, 2016
, the Company repaid
$134.0 million
, and as a result, the next required payments will be on the maturity dates. The Company is also required to make mandatory prepayments, subject to specified exceptions, from excess cash flow and with the proceeds of asset sales, debt issuances and specified other events.
The Company's obligations under the credit facility are guaranteed by substantially all of its direct and indirect domestic subsidiaries and are secured by a lien on substantially all of the Company's tangible and intangible property and by a pledge of all of the equity interests in its direct and indirect domestic subsidiaries.
The credit facility includes various restrictive covenants including the maximum ratio of consolidated funded debt to consolidated EBITDA (
4.25
to 1.00 as of
March 31, 2016
decreasing to
3.25
to 1.00 on March 31, 2018). The credit facility also contains certain customary limitations including, among other terms and conditions, the Company's ability to incur additional indebtedness, engage in mergers and acquisitions, and declare dividends. At
March 31, 2016
the Company had a ratio of consolidated funded debt to consolidated EBITDA of
2.80
to 1.00.
At
March 31, 2016
the Company was in compliance with all of its debt covenants and had
$112.5 million
of borrowing available under the revolving credit facility.
7. Commitments and Contingencies
The Company has entered into various non-cancelable operating leases, primarily related to its facilities and certain office equipment used in the ordinary course of business. The Company lea
ses
two
properties own
ed by related parties. Rent expense for these two properties was
$0.3 million
for the
three months ended March 31, 2016
and
2015
.
The Company carries large retention policies for its workers’ compensation liability exposures. The workers' compensation loss reserves are based upon an actuarial report obtained from a third party and determined based on claims filed and claims incurred but not reported. The Company accounts for claims incurred but not yet reported based on estimates derived from historical claims experience and current trends of industry data. Changes in estimates, differences in estimates, and actual payments for claims, are recognized in the period that the estimates
changed or the payments were made. The workers' compensation loss reserves were approximately
$1.6 million
and
$1.8 million
, net of anticipated insurance and indemnification recoveries of
$13.3 million
and
$13.2 million
, at
March 31, 2016
and
December 31, 2015
, respectively. The Company has unused stand-by letters of credit outstanding to secure obligations for workers’ compensation claims with various insurance carriers. The unused stand-by letters of credit at
March 31, 2016
and
December 31, 2015
were
$3.5 million
.
The Company is subject to contingent consideration agreements entered into in connection with certain of its acquisitions. If the acquired businesses
meet predetermined targets, the Company is obligated to make additional cash payments in accordance with the terms of
such contingent consideration agreements, see note "
8. Fair Value Measurements
."
Certain employees participate in the Company’s Change in Control Severance Plan, or have separate agreements that provide for certain benefits in the event of termination at the Company's convenience or following a change in control, as defined by the plan or agreement. Generally, these benefits are based on the employee’s length of service and position with the Company and include, severance, continuation of health insurance and in certain cases acceleration of vesting of option or stock awards.
Legal Proceedings
The Company is involved in various legal proceedings, claims and litigation arising in the ordinary course of business. Based on the facts currently available, the Company does not believe that the disposition of matters that are pending or asserted will have a material effect on its consolidated financial statements.
8. Fair Value Measurements
The recorded values of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate their fair value based on their short-term nature. Long-term debt recorded in the Company’s condensed consolidated balance sheet at
March 31, 2016
was
$723.2 million
(net of
$17.8 million
of unamortized deferred loan costs, see "Note
6. Long-Term Debt
"). The f
air value of the long-term debt at that same date was
$744.5 million
as
determined using the quoted price technique, based on Level 2 inputs (significant observable inputs other than quoted prices for identical assets in active markets) from the fair value hierarchy, and included the yields of comparable companies with similar credit characteristics
.
Related to its acquisitions, at
March 31, 2016
, the Company had obligations to pay contingent consideration in cash if certain performance targets were met. The fair value of this contingent consideration was determined using an expected present value technique. Expected cash flows were determined using the probability-weighted average of possible outcomes that would occur should certain financial metrics be reached. There is no market data available to use in valuing the contingent consideration, therefore, the Company developed its own assumptions related to the future financial performance of the businesses to evaluate the fair value of these liabilities. As such, the contingent consideration is classified within Level 3 inputs (unobservable inputs) from the fair value hierarchy.
The fair value of the liability for contingent consideration is established at the time of the acquisition and finalized by the end of the measurement period. Its fair value i
s then
remeasured on a
recurring basis with c
hanges due to the accretion of the present value discount, recorded in interest expense and changes related to new developments in expected performance, recorded in SG&A. At
March 31, 2016
, the contingent consideration was determined to be
$21.6 million
and is included in other current liabilities. The Company expects to make the contingent consideration payments within the next three months. At December 31, 2015, contingent consideration wa
s
$21.0 million
and was included in other current liabilities. The performance period for these contingent consideration arrangements ended on December 31, 2015.
The following table summarizes the balance of the contingent consideration and changes for the periods presented (in thousands):
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
March 31,
|
|
2016
|
|
2015
|
Balance at beginning of period
|
$
|
(20,981
|
)
|
|
$
|
(3,000
|
)
|
Additions for acquisitions
|
—
|
|
|
—
|
|
Payments on contingent consideration
|
—
|
|
|
—
|
|
Fair value adjustment
|
(613
|
)
|
|
—
|
|
Foreign currency translation adjustment
|
—
|
|
|
—
|
|
Balance at end of period
|
$
|
(21,594
|
)
|
|
$
|
(3,000
|
)
|
Certain assets and liabilities, such as goodwill, are not measured at fair value on an ongoing basis but are subject to fair value adjustments in certain circumstances (e.g., when there is evidence of impairment). For
the
three months ended
March 31, 2016
and 2015, no fair value adjustments were required for non-financial assets or liabilities.
9. Accumulated Other Comprehensive Loss
The accumulated other comprehensive loss balance at
March 31, 2016
and
December 31, 2015
, and the activity during the
three months ended
March 31, 2016
, consists of foreign currency translation adjustments.
10. Stock-based Compensation
On
March 31, 2016
, the Company issued
128,518
shares of common stock under its Employee Stock Purchase Plan, as amended (the "ESPP").
Stock-based compensation expense, including the ESPP, was
$6.9 million
and
$4.0 million
for the
three months ended
March 31, 2016
and
2015
, respectively, which was included in SG&A expense.
11. Earnings Per Share
The following is a reconciliation of the shares used to compute basic and diluted earnings per share (in thousands):
|
|
|
|
|
|
|
|
Three Months Ended
|
|
March 31,
|
|
2016
|
|
2015
|
Weighted average number of common shares outstanding used to compute basic earnings per share
|
53,147
|
|
|
51,519
|
|
Dilutive effect of stock-based awards
|
497
|
|
|
690
|
|
Number of shares used to compute diluted earnings per share
|
53,644
|
|
|
52,209
|
|
There were
473,000
share equivalents outstanding during the three months ended March 31, 2016 that were excluded from the computation of diluted earnings per share because the exercise price for these options was greater than the average market price of the Company’s shares of common stock and became anti-dilutive when applying the treasury stock method. During the three months ended March 31, 2015 there were no significant share equivalents outstanding that were excluded from the computation of diluted earnings per share because they became anti-dilutive when applying the treasury stock method.
12. Income Taxes
For interim reporting periods, the Company estimates its full-year income and the related income tax expense for each jurisdiction in which the Company operates. Changes in the geographical mix, permanent differences or estimated level of annual pre-tax income can impact the Company’s actual effective rate.
13. Segment Reporting
On Assignment provides services through
two
operating segments, the Apex Segment and the Oxford Segment, with each addressing different sectors of the professional staffing market with distinct business models attuned to those sectors. Businesses in the Apex Segment predominately serve markets with a large and local talent pool, and provide a full range of skills through a network of local offices where clients most value relationship, speed, reliability and price. The Apex Segment provides a broad spectrum of technical, scientific and creative professionals for contract, contract-to-hire and permanent placement positions to Fortune 1000 and mid-market clients across the United States. Our businesses in this segment include Apex Systems, Lab Support and Creative Circle. Businesses in the Oxford Segment predominately serve markets with higher-end, specialized skills through a combination of national recruiting centers and local offices where clients most value the unique skill of the candidate and speed of response. The Oxford Segment provides specialized, niche staffing and consulting services in select skill and geographic markets. Our businesses in this segment include Oxford, CyberCoders and Life Sciences Europe.
Effective January 1, 2016, there were two changes to the Company's segment configuration: 1) the Apex Segment now includes a small clinical research business which was previously included in the Oxford Segment, and 2) costs associated with personnel located at our Corporate office that have shared services roles and support certain of our businesses, primarily within the Oxford Segment, are now presented in the segments they support whereas previously they were presented within Corporate. For comparability purposes, prior periods have been adjusted to reflect these changes.
The Company’s management evaluates the performance of each segment primarily based on revenues, gross profit and operating income. The information in the following tables is derived directly from the segments’ internal financial reporting used for corporate management purposes. The Company's management does not evaluate, manage or measure performance of segments using asset information, and such information is not readily available. Accordingly, assets by reportable segment are not disclosed.
The following tables present revenues, gross profit, operating income and amortization by reportable segment (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
March 31, 2016
|
|
Apex
|
|
Oxford
|
|
Corporate
(1)
|
|
Total
|
Revenues
|
$
|
433,155
|
|
|
$
|
148,885
|
|
|
$
|
—
|
|
|
$
|
582,040
|
|
Gross profit
|
126,144
|
|
|
61,638
|
|
|
—
|
|
|
187,782
|
|
Operating income
|
39,986
|
|
|
12,760
|
|
|
(14,989
|
)
|
|
37,757
|
|
Amortization
|
8,590
|
|
|
1,554
|
|
|
—
|
|
|
10,144
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
March 31, 2015
|
|
Apex
|
|
Oxford
(2)
|
|
Corporate
(1)
|
|
Total
|
Revenues
|
$
|
295,971
|
|
|
$
|
134,074
|
|
|
$
|
—
|
|
|
$
|
430,045
|
|
Gross profit
|
80,152
|
|
|
55,723
|
|
|
—
|
|
|
135,875
|
|
Operating income
|
22,896
|
|
|
12,713
|
|
|
(10,538
|
)
|
|
25,071
|
|
Amortization
|
3,522
|
|
|
1,347
|
|
|
—
|
|
|
4,869
|
|
|
|
(1)
|
Corporate expenses primarily consist of consolidated stock-based compensation expense, compensation for corporate employees, acquisition, integration and strategic planning expenses, public company expenses, and depreciation expense for corporate assets.
|
|
|
(2)
|
During the quarter ended June 30, 2015, due to management changes, the Company realigned its former Life Sciences Europe Segment to be included in the Oxford Segment. Prior periods have been adjusted to reflect this change.
|
The following table presents revenues by type (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
March 31,
|
|
2016
|
|
%
|
|
2015
|
|
%
|
Revenues:
|
|
|
|
|
|
|
|
Assignment
|
$
|
549,552
|
|
|
94.4
|
%
|
|
$
|
406,141
|
|
|
94.4
|
%
|
Permanent placement
|
32,488
|
|
|
5.6
|
%
|
|
23,904
|
|
|
5.6
|
%
|
|
$
|
582,040
|
|
|
100.0
|
%
|
|
$
|
430,045
|
|
|
100.0
|
%
|
The Company operates internationally, with operations mainly in the United States, Europe, and Canada. The following table presents revenues by geographic location (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
March 31,
|
|
2016
|
|
%
|
|
2015
|
|
%
|
Revenues:
|
|
|
|
|
|
|
|
Domestic
|
$
|
554,438
|
|
|
95.3
|
%
|
|
$
|
410,756
|
|
|
95.5
|
%
|
Foreign
|
27,602
|
|
|
4.7
|
%
|
|
19,289
|
|
|
4.5
|
%
|
|
$
|
582,040
|
|
|
100.0
|
%
|
|
$
|
430,045
|
|
|
100.0
|
%
|